Reuters logo
Novartis gets wider EU approval for Zykadia in lung cancer
June 29, 2017 / 5:30 AM / 4 months ago

Novartis gets wider EU approval for Zykadia in lung cancer

ZURICH, June 29 (Reuters) - The European Commission has approved expanding the use of Zykadia (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, Swiss drugmaker Novartis said on Thursday.

In May, the U.S. Food and Drug Administration approved the expanded use of Zykadia to include the first-line treatment of patients with metastatic NSCLC whose tumours are ALK-positive. (Reporting by Michael Shields, editing by John Revill)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below